Usefulness of suPAR as a biological marker in patients with systemic inflammation or infection: A systematic review

Intensive Care Medicine

Volumn 38, Issue 9, 2012, Pages 1418-1428

  Backes, Yara ^a,b   Van Der Sluijs, Koenraad F ^b   Mackie, David P ^c   Tacke, Frank ^d   Koch, Alexander ^d   Tenhunen, Jyrki J ^e,f   Schultz, Marcus J ^a,b  

^a UNIVERSITY OF AMSTERDAM   (Netherlands)

^b ACADEMIC MEDICAL CENTER   (Netherlands)

^c RED CROSS HOSPITAL   (Netherlands)

^d UNIVERSITY HOSPITAL RWTH AACHEN   (Germany)

^e TAMPERE UNIVERSITY HOSPITAL   (Finland)

^f UPPSALA UNIVERSITY   (Sweden)

Author keywords

Biomarker; Critical illness; Intensive care; Sepsis; Soluble uPAR; Soluble urokinase plasminogen activator receptor (suPAR)

Indexed keywords

ANTIINFECTIVE AGENT; BIOLOGICAL MARKER; SOLUBLE UROKINASE TYPE PLASMINOGEN ACTIVATOR RECEPTOR; UNCLASSIFIED DRUG; UROKINASE RECEPTOR;

ANTIMICROBIAL THERAPY; BACTEREMIA; CLINICAL EFFECTIVENESS; CRITICALLY ILL PATIENT; DIAGNOSTIC VALUE; DISEASE CLASSIFICATION; DISEASE MARKER; DISEASE SEVERITY; HUMAN; MORTALITY; MULTIPLE ORGAN FAILURE; PATIENT CARE; PROGNOSIS; REVIEW; SEPSIS; SYSTEMATIC REVIEW; SYSTEMIC INFLAMMATORY RESPONSE SYNDROME;

BIOLOGICAL MARKERS; CRITICAL ILLNESS; HUMANS; INTENSIVE CARE UNITS; MULTIPLE ORGAN FAILURE; PROGNOSIS; RECEPTORS, UROKINASE PLASMINOGEN ACTIVATOR; RISK ASSESSMENT; SEPSIS; SEVERITY OF ILLNESS INDEX; SYSTEMIC INFLAMMATORY RESPONSE SYNDROME;

EID: 84866730075     PISSN: 03424642     EISSN: 14321238     Source Type: Journal    
DOI: 10.1007/s00134-012-2613-1     Document Type: Review

References (52)

1. Stephens RW, Pedersen AN, Nielsen HJ, Hamers MJ, Høyer-Hansen G, Rønne E, Dybkjaer E, Danø K, Brünner N (1997) ELISA determination of soluble urokinase receptor in blood from healthy donors and cancer patients. Clin Chem 43:1868-1876
2. Sier CF, Stephens R, Bizik J, Mariani A, Bassan M, Pedersen N, Frigerio L, Ferrari A, Danø K, Brünner N, Blasi F (1998) The level of urokinase-type plasminogen activator receptor is increased in serum of ovarian cancer patients. Cancer Res 58:1843-1849
3. Ostrowski SR, Katzenstein TL, Piironen T, Gerstoft J, Pedersen BK, Ullum H (2004) Soluble urokinase receptor levels in plasma during 5 years of highly active antiretroviral therapy in HIV-1-infected patients. J Acquir Immune Defic Syndr 35:337-342
4. Perch M, Kofoed P, Fischer TK, Có F, Rombo L, Aaby P, Eugen-Olsen J (2004) Serum levels of soluble urokinase plasminogen activator receptor is associated with parasitemia in children with acute Plasmodium falciparum malaria infection. Parasite Immunol 26:207-211
5. Ostrowski SR, Ullum H, Goka BQ, Høyer-Hansen G, Obeng-Adjei G, Pedersen BK, Akanmori BD, Kurtzhals JA (2005) Plasma concentrations of soluble urokinase-type plasminogen activator receptor are increased in patients with malaria and are associated with a poor clinical or a fatal outcome. J Infect Dis 191:1331-1341
6. Eugen-Olsen J, Gustafson P, Sidenius N, Fischer TK, Parner J, Aaby P, Gomes VF, Lisse I (2002) The serum level of soluble urokinase receptor is elevated in tuberculosis patients and predicts mortality during treatment: a community study from Guinea-Bissau. Int J Tuberc Lung Dis 6:686-692
7. Ostrowski SR, Ravn P, Hoyer-Hansen G, Ullum H, Andersen AB (2006) Elevated levels of soluble urokinase receptor in serum from mycobacteria infected patients: still looking for a marker of treatment efficacy. Scand J Infect Dis 38:1028-1032
8. Garcia-Monco JC, Coleman JL, Benach JL (2002) Soluble urokinase receptor (uPAR, CD 87) is present in serum and cerebrospinal fluid in patients with neurologic diseases. J Neuroimmunol 129:216-223
9. Slot O, Brunner N, Locht H, Oxholm P, Stephens RW (1999) Soluble urokinase plasminogen activator receptor in plasma of patients with inflammatory rheumatic disorders: increased concentrations in rheumatoid arthritis. Ann Rheum Dis 58:488-492
10. Pliyev BK, Menshikov MY (2010) Release of the soluble urokinase-type plasminogen activator receptor (suPAR) by activated neutrophils in rheumatoid arthritis. Inflammation 33:1-9
11. Andersen ES, Ruhwald M, Moessner B, Christensen PB, Andersen O, Eugen-Olsen J, Weis N (2011) Twelve potential fibrosis markers to differentiate mild liver fibrosis from cirrhosis in patients infected with chronic hepatitis C genotype 1. Eur J Clin Microbiol Infect Dis 30:761-766
12. Lonnkvist MH, Theodorsson E, Holst M, Ljung T, Hellström PM (2011) Blood chemistry markers for evaluation of inflammatory activity in Crohn's disease during infliximab therapy. Scand J Gastroenterol 46:420-427
13. Stephens RW, Nielsen HJ, Christensen IJ, Thorlacius-Ussing O, Sørensen S, Danø K, Brünner N (1999) Plasma urokinase receptor levels in patients with colorectal cancer: relationship to prognosis. J Natl Cancer Inst 91:869-874
14. Brunner N, Nielsen HJ, Hamers M, Christensen IJ, Thorlacius-Ussing O, Stephens RW (1999) The urokinase plasminogen activator receptor in blood from healthy individuals and patients with cancer. APMIS 107:160-167
15. Sidenius N, Sier CF, Ullum H, Pedersen BK, Lepri AC, Blasi F, Eugen-Olsen J (2000) Serum level of soluble urokinase-type plasminogen activator receptor is a strong and independent predictor of survival in human immunodeficiency virus infection. Blood 96:4091-4095
16. Ostrowski SR, Piironen T, Hoyer-Hansen G, Gerstoft J, Pedersen BK, Ullum H (2005) High plasma levels of intact and cleaved soluble urokinase receptor reflect immune activation and are independent predictors of mortality in HIV-1-infected patients. J Acquir Immune Defic Syndr 39:23-31
17. Mizukami IF, Faulkner NE, Gyetko MR, Sitrin RG, Todd RF 3rd (1995) Enzyme-linked immuno-absorbent assay detection of a soluble form of urokinase plasminogen activator receptor in vivo. Blood 86:203-211
18. Bossuyt PM, Reitsma JB, Bruns DE, Gatsonis CA, Glasziou PP, Irwig LM, Lijmer JG, Moher D, Rennie D, de Vet HC, Standards for Reporting of Diagnostic Accuracy (2003) Towards complete and accurate reporting of studies of diagnostic accuracy: the STARD initiative. Standards for Reporting of Diagnostic Accuracy. Clin Chem 49:1-6
19. Bossuyt PM, Reitsma JB, Bruns DE, Gatsonis CA, Glasziou PP, Irwig LM, Moher D, Rennie D, de Vet HC, Lijmer JG (2003) The STARD statement for reporting studies of diagnostic accuracy: explanation and elaboration. Clin Chem 49:7-18
20. Molkanen T, Ruotsalainen E, Thorball CW, Järvinen A (2011) Elevated soluble urokinase plasminogen activator receptor (suPAR) predicts mortality in Staphylococcus aureus bacteremia. Eur J Clin Microbiol Infect Dis 30:1417-1424
21. Moller HJ, Moestrup SK, Weis N, Wejse C, Nielsen H, Pedersen SS, Attermann J, Nexø E, Kronborg G (2006) Macrophage serum markers in pneumococcal bacteremia: prediction of survival by soluble CD163. Crit Care Med 34:2561-2566
22. Kofoed K, Andersen O, Kronborg G, Tvede M, Petersen J, Eugen-Olsen J, Larsen K (2007) Use of plasma C-reactive protein, procalcitonin, neutrophils, macrophage migration inhibitory factor, soluble urokinase-type plasminogen activator receptor, and soluble triggering receptor expressed on myeloid cells-1 in combination to diagnose infections: a prospective study. Crit Care 11:R38
23. Kofoed K, Eugen-Olsen J, Petersen J, Larsen K, Andersen O (2008) Predicting mortality in patients with systemic inflammatory response syndrome: an evaluation of two prognostic models, two soluble receptors, and a macrophage migration inhibitory factor. Eur J Clin Microbiol Infect Dis 27:375-383
24. Kofoed K, Schneider UV, Scheel T, Andersen O, Eugen-Olsen J (2006) Development and validation of a multiplex add-on assay for sepsis biomarkers using xMAP technology. Clin Chem 52:1284-1293
25. Koch A, Voigt S, Kruschinski C, Sanson E, Dückers H, Horn A, Yagmur E, Zimmermann H, Trautwein C, Tacke F (2011) Circulating soluble urokinase plasminogen activator receptor is stably elevated during the first week of treatment in the intensive care unit and predicts mortality in critically ill patients. Crit Care 15:R63
26. Wittenhagen P, Kronborg G, Weis N, Nielsen H, Obel N, Pedersen SS, Eugen-Olsen J (2004) The plasma level of soluble urokinase receptor is elevated in patients with Streptococcus pneumoniae bacteraemia and predicts mortality. Clin Microbiol Infect 10:409-415
27. Huttunen R, Syrjanen J, Vuento R, Hurme M, Huhtala H, Laine J, Pessi T, Aittoniemi J (2011) Plasma level of soluble urokinase-type plasminogen activator receptor as a predictor of disease severity and case fatality in patients with bacteraemia: a prospective cohort study. J Intern Med 270:32-40
28. Florquin S, van den Berg JG, Olszyna DP, Claessen N, Opal SM, Weening JJ, van der Poll T (2001) Release of urokinase plasminogen activator receptor during urosepsis and endotoxemia. Kidney Int 59:2054-2061
29. Bone RC, Balk RA, Cerra FB, Dellinger RP, Fein AM, Knaus WA, Schein RM, Sibbald WJ, ACCP/SCCM Consensus Conference Committee (2009) Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. The ACCP/SCCM Consensus Conference Committee. American College of Chest Physicians/Society of Critical Care Medicine 1992. Chest 136 (5 suppl):e28
30. Pierrakos C, Vincent JL (2010) Sepsis biomarkers: a review. Crit Care 14:R15
31. Christ-Crain M, Muller B (2007) Biomarkers in respiratory tract infections: diagnostic guides to antibiotic prescription, prognostic markers and mediators. Eur Respir J 30:556-573
32. Kibe S, Adams K, Barlow G (2011) Diagnostic and prognostic biomarkers of sepsis in critical care. J Antimicrob Chemother 66(Suppl 2): ii33-ii40
33. Standage SW, Wong HR (2011) Biomarkers for pediatric sepsis and septic shock. Expert Rev Anti Infect Ther 9:71-79
34. Becker KL, Snider R, Nylen ES (2008) Procalcitonin assay in systemic inflammation, infection, and sepsis: clinical utility and limitations. Crit Care Med 36:941-952
35. Schuetz P, Christ-Crain M, Muller B (2009) Procalcitonin and other biomarkers to improve assessment and antibiotic stewardship in infections-hope for hype? Swiss Med Wkly 139:318-326
36. Sier CF, Sidenius N, Mariani A, Aletti G, Agape V, Ferrari A, Casetta G, Stephens RW, Brünner N, Blasi F (1999) Presence of urokinase-type plasminogen activator receptor in urine of cancer patients and its possible clinical relevance. Lab Invest 79:717-722
37. Thuno M, Macho B, Eugen-Olsen J (2009) suPAR: the molecular crystal ball. Dis Markers 27:157-172
38. Ossowski L, Aguirre-Ghiso JA (2000) Urokinase receptor and integrin partnership: coordination of signaling for cell adhesion, migration and growth. Curr Opin Cell Biol 12:613-620
39. Resnati M, Guttinger M, Valcamonica S, Sidenius N, Blasi F, Fazioli F (1996) Proteolytic cleavage of the urokinase receptor substitutes for the agonistinduced chemotactic effect. EMBO J 15:1572-1582
40. Mondino A, Blasi F (2004) uPA and uPAR in fibrinolysis, immunity and pathology. Trends Immunol 25:450-455
41. Rijneveld AW, Levi M, Florquin S, Speelman P, Carmeliet P, van der Poll T (2002) Urokinase receptor is necessary for adequate host defense against pneumococcal pneumonia. J Immunol 168:3507-3511
42. Selleri C, Montuori N, Ricci P, Visconte V, Carriero MV, Sidenius N, Serio B, Blasi F, Rotoli B, Rossi G, Ragno P (2005) Involvement of the urokinase-type plasminogen activator receptor in hematopoietic stem cell mobilization. Blood 105:2198-2205
43. Park YJ, Liu G, Tsuruta Y, Lorne E, Abraham E (2009) Participation of the urokinase receptor in neutrophil efferocytosis. Blood 114:860-870
44. Wiersinga WJ, Kager LM, Hovius JW, van der Windt GJ, de Vos AF, Meijers JC, Roelofs JJ, Dondorp A, Levi M, Day NP, Peacock SJ, van der Poll T (2010) Urokinase receptor is necessary for bacterial defense against pneumonia-derived septic melioidosis by facilitating phagocytosis. J Immunol 184:3079-3086
45. McMaken S, Exline MC, Mehta P, Piper M, Wang Y, Fischer SN, Newland CA, Schrader CA, Balser SR, Sarkar A, Baran CP, Marsh CB, Cook CH, Phillips GS, Ali NA (2011) Thrombospondin-1 contributes to mortality in murine sepsis through effects on innate immunity. PLoS ONE 6:e19654
46. Quach S, Hennessy DA, Faris P, Fong A, Quan H, Doig C (2009) A comparison between the APACHE II and Charlson index score for predicting hospital mortality in critically ill patients. BMC Health Serv Res 9:129
47. Le Gall JR, Lemeshow S, Saulnier F (1993) A new simplified acute physiology score (SAPS II) based on a European/North American multicenter study. JAMA 270:2957-2963
48. Mirsaeidi M, Peyrani P, Ramirez JA, Improving Medicine through Pathway Assessment of Critical Therapy of Hospital-Acquired Pneumonia (IMPACT-HAP) Investigators (2009) Predicting mortality in patients with ventilator-associated pneumonia: the APACHE II score versus the new IBMP-10 score. Clin Infect Dis 49:72-77
49. Riisbro R, Christensen IJ, Hogdall C, Brünner N, Høgdall E (2001) Soluble urokinase plasminogen activator receptor measurements: influence of sample handling. Int J Biol Markers 16:233-239
50. Kumar A, Roberts D, Wood KE, Light B, Parrillo JE, Sharma S, Suppes R, Feinstein D, Zanotti S, Taiberg L, Gurka D, Kumar A, Cheang M (2006) Duration of hypotension before initiation of effective antimicrobial therapy is the critical determinant of survival in human septic shock. Crit Care Med 34:1589-1596
51. Moran JL, Bristow P, Solomon PJ, George C, Hart GK, Australian and New Zealand Intensive Care Society Database Management Committee (ADMC) (2008) Mortality and lengthofstay outcomes, 1993-2003, in the binational Australian and New Zealand intensive care adult patient database. Crit Care Med 36:46-61
52. Kaufmann PA, Smolle KH, Krejs GJ (2009) Short-and long-term survival of nonsurgical intensive care patients and its relation to diagnosis, severity of disease, age and comorbidities. Curr Aging Sci 2:240-248